Concord Biotech Limited (NSE: CONCORDBIO), ISIN INE338H01029 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
CONCORDBIO last traded at ₹1330.10 (+6.05%), with a 52-week range of ₹987.05 to ₹1879.05 (as of 30 Jul 2026).
Shareholding as of Jun 2026: promoters 44.08%, FIIs 7.52%, DIIs 9.36%, mutual funds 4.40%.
EquiSense Score (ECS): 58/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.